Aileron Therapeutics Inc. (ALRN)

2.17
NASDAQ : Health Technology
Prev Close 2.25
Day Low/High 2.11 / 2.20
52 Wk Low/High 1.75 / 12.70
Avg Volume 95.50K
Exchange NASDAQ
Shares Outstanding 14.74M
Market Cap 33.16M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oversold Conditions For Aileron Therapeutics (ALRN)

Oversold Conditions For Aileron Therapeutics (ALRN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aileron Therapeutics Enters Oversold Territory (ALRN)

Aileron Therapeutics Enters Oversold Territory (ALRN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aileron Therapeutics is Now Oversold (ALRN)

Aileron Therapeutics is Now Oversold (ALRN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aileron Therapeutics Announces Oral Presentations On Lead Product Candidate ALRN-6924 At The 59th American Society Of Hematology Annual Meeting

Aileron Therapeutics Announces Oral Presentations On Lead Product Candidate ALRN-6924 At The 59th American Society Of Hematology Annual Meeting

Two abstracts selected for oral presentations, highlighting the potential of p53-reactivating ALRN-6924 in the treatment of PTCL and AML

Aileron Therapeutics Announces Presentation Of Preclinical Data With ALRN-6924 At The International Society Of Experimental Hematology Annual Scientific Meeting

Aileron Therapeutics Announces Presentation Of Preclinical Data With ALRN-6924 At The International Society Of Experimental Hematology Annual Scientific Meeting

Collaboration with Albert Einstein College of Medicine studies effect of targeting MDMX and MDM2 with ALRN-6924 in AML

Here's the Latest on Four New Biotech IPOs

Here's the Latest on Four New Biotech IPOs

Four biotech companies recently joined the Nasdaq.

American Learning Corporation Reports First Quarter Results

American Learning Corporation Reports First Quarter Results

American Learning Corporation (the “Company”) (NASDAQ:ALRN) announced revenues of $879,897 and a net loss of $142,543 ($.

American Learning Corporation Reports Completion Of Private Placement

American Learning Corporation Reports Completion Of Private Placement

American Learning Corporation (the “Company”) (NASDAQ:ALRN) announced that on June 30, 2011, the Company completed a private placement of 164,715 shares of the Company’s common stock, par value $.

American Learning Corporation Reports Fourth Quarter And Year End Results

American Learning Corporation Reports Fourth Quarter And Year End Results

American Learning Corporation (the “Company”) (NASDAQ: ALRN) announced revenues of $2,984,412 and a net loss of $1,115,706 ($.

American Learning Corporation Announces Proposed Acquisition And Sale Of Certain Assets

American Learning Corporation Announces Proposed Acquisition And Sale Of Certain Assets

American Learning Corporation (the “Company”) (NASDAQ:ALRN) is pleased to announce it has signed a non-binding letter of intent to acquire an 80% interest in an east coast company which provides educational and ...

American Learning Corporation Reports Third Quarter Results

American Learning Corporation Reports Third Quarter Results

American Learning Corporation (the “Company”) (NASDAQ:ALRN) announced that the Company had achieved increases in revenues and decreases in its net losses for the three and nine months ended December 31, 2010 ...

American Learning Corporation Regains Compliance With Nasdaq Marketplace Rules

American Learning Corporation Regains Compliance With Nasdaq Marketplace Rules

American Learning Corporation (the “Company”) (NASDAQ:ALRN) today announced that the Company received a notice from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company has met the...

American Learning Corporation Reports Second Quarter Results

American Learning Corporation Reports Second Quarter Results

American Learning Corporation (the “Company”) (NASDAQ: ALRN) announced revenues of $1,502,806 and a net loss of $365,620 ($.

Nasdaq Panel Grants American Learning Corporation’s Request For Continued Listing

American Learning Corporation (the “Company”) (NASDAQ:ALRN) today announced that a Nasdaq Listing Qualifications Panel (the “Panel”) has granted the Company’s request for an extension of time, as...

American Learning Corporation To Appeal Nasdaq Delisting Notice

American Learning Corporation (the “Company”) (NASDAQ:ALRN) received notification from The Nasdaq Stock Market (“Nasdaq”) that it has not regained compliance with The Nasdaq Capital Market's minimum...

American Learning Corporation Reports First Quarter Results

American Learning Corporation (the “Company”) (NASDAQ: ALRN) announced revenues of $2,266,090 and a net loss of $49,970 ($.

American Learning Corporation Reports Fourth Quarter And Year End Results

American Learning Corporation (the “Company”) (NASDAQ: ALRN) announced revenues of $6,973,752 and a net loss of $823,142 ($.